Phase II trialPhase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
Section snippets
Patient selection
Patients entered the study from January 2000 to July 2001 based on the following criteria: histological or cytological proven adenocarcinoma of the pancreas, inoperable judged by the surgeon, the radiologist and the oncologist, UICC stage T1-3 N0 M0 (=AJCC stages I–II)[14], no more than 6 cm in largest diameter, tumour visualized on CT-scan, WHO/ECOG performance status 0–2, and informed consent by the patient. All patients underwent CT-scan, 14 patients went through endoscopic ultrasonography
Results
A total number of 22 patients with pancreatic cancer were included in the study. Of these, 19 had an inoperable primary pancreatic cancer and three had a recurrence after a Whipple resection, two with a local recurrence and one with a lymph node metastasis. Patient characteristics are given in Table 1. All patients had non-resectable tumours due to invasion of vessels or other adjacent structures. Twelve females and 10 males were included. Median age was 61 (43–76) years. At the time of
Discussion
Extracranial stereotactic radiotherapy (ESRT) based on the SBF was introduced at Karolinska Hospital, Stockholm in the early 1990s [12]. A large number of SBF's have been distributed around Europe, North America, and Asia, and a large number of patients have undergone ESRT based on principles of the SBF or other custom made systems. Even though the number of patients treated with ESRT is high, only limited scientific evidence supports the treatment. So far, only few prospective and few
Acknowledgements
This study was supported by a grant from the Kloppenborg X-knife foundation.
References (25)
Pancreatic adenocarcinoma
Curr Probl Cancer
(1996)- et al.
Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma
Int J Radiat Oncol Biol Phys
(2001) - et al.
Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC)
Int J Radiat Oncol Biol Phys
(2003) - et al.
Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience
Int J Radiat Oncol Biol Phys
(2001) - et al.
Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame
Int J Radiat Oncol Biol Phys
(2002) - et al.
Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography
Ann Surg
(1995) - et al.
Pancreatic carcinoma in perspective. A continuing challenge
Cancer
(1996) - et al.
Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors
Ann Surg
(1996) - et al.
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphnodeadenectomy for periampullary adenocarcinoma. Part 2
Ann Surg
(2002) - et al.
Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma
Cancer
(2000)
Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy
Cancer
Combined modality therapy for stage II and stage III pancreatic carcinoma
J Clin Oncol
Cited by (291)
Undoing the Layers: Magnetic Resonance Imaging/Advanced Image Guidance and Adaptive Radiation Therapy
2024, International Journal of Radiation Oncology Biology PhysicsStereotactic body radiotherapy for pancreatic cancer – A systematic review of prospective data
2024, Clinical and Translational Radiation OncologyTrials and Technology to Advance Upper Gastrointestinal Oncology: Imagination, Imaging, and the Intertwined Imperfections
2024, International Journal of Radiation Oncology Biology PhysicsImpact of Short-Course Palliative Radiation Therapy on Pancreatic Cancer-Related Pain: Prospective Phase 2 Nonrandomized PAINPANC Trial
2024, International Journal of Radiation Oncology Biology PhysicsStereotactic body radiotherapy in pancreatic adenocarcinoma
2024, Hepatobiliary and Pancreatic Diseases International